The randomized controlled trial about the regression of atherosclerosis by using pioglitazone added to statin treatment

The randomized controlled trial about the regression of atherosclerosis by using pioglitazone added to statin treatment - Research about the regression of atherosclerosis by pioglitazone therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000480

Enrollment

Registered

2006-09-26

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

15 to 45mg pioglitazone is administered for the patient for six months once per day added to statin therapy statin therapy only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The non-diabetic patients who have 50% or more of stenosis in coronary artery, and their serum LDL levels were controlled less than 100mg/dl under the statin treatment.

Exclusion criteria

Exclusion criteria: anamnesis of cardiac insufficiency LVEF<40% critical hepatopathy(an increase the twice as many fiducial point of AST,ALT, ALP,etc, and choloplania) renal dysfunction(more than serum creatine 2.0mg/dl) anaphylactic anamnesis to piogritazon critical trauma, preoperative, serious infectious desease, pregnancy

Design outcomes

Primary

Measure	Time frame
carotid intima-media thickness by carotid artery echo if possible, coronary angiography and intravascular ultrasound	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026